Skip to Content

Pluristem Therapeutics Will Present the Phase I Study for PLX-PAD in Critical Limb Ischemia at MSC2009 Regenerative Medicine and Adult Stem Cell Therapy Conference

HAIFA, Israel--(BUSINESS WIRE)--Aug 11, 2009 - Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that the Phase I study for PLX-PAD in critical limb ischemia (CLI) will be presented at the MSC2009 Regenerative Medicine and Adult Stem Cell Therapy conference.

William Prather R.Ph., M.D., Pluristem's senior vice president corporate development, will present the study design in an oral presentation titled “Update on Pluristem's Phase I Clinical Trial Using PLX-PAD in Critical Limb Ischemia” at noon EDT, Wednesday, Aug. 19. Information on the Phase I study of PLX-PAD for CLI will also be available on a poster presentation. MSC2009 will be held on Aug. 17-19, 2009, at the Cleveland Marriott Downtown at Key Center, Cleveland, Ohio.

“This will be the first scientific forum where we will be informing our peers in the adult stem cell community on our Phase I dose escalating clinical studies using PLX-PAD,” said Zami Aberman, chairman, president and CEO of Pluristem. “This study is ongoing in Europe, enrolling patients diagnosed with critical limb ischemia, the end stage of peripheral artery disease.”

About MSC 2009

The Regenerative Medicine and Adult Stem Cell Therapy Conference (MSC2009) will be held on August 17-19, 2009 in Cleveland, Ohio ( MSC2009 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. The focus of the conference is on the isolation, characterization, purity, plasticity and clinical uses of adult stem cells from a variety of human and animal tissues including bone marrow, fat, cord blood and matrix, placenta and amniotic fluid.

About the National Center for Regenerative Medicine

The National Center for Regenerative Medicine (NCRM; in Cleveland, OH, brings together over 120 researchers and physicians from Case Western Reserve University, the Cleveland Clinic and University Hospitals Case Medical Center. The NCRM provides a comprehensive approach, including basic through clinical as well as biomedical and tissue engineering research approaches, to develop new adult (non-embryonic) stem cell therapies for patients suffering from chronic and debilitating diseases including heart disease, cancer, genetic disorders, orthopedics, musculoskeletal and neurodegenerative diseases and injuries such as multiple sclerosis and spinal cord injury.

About Pluristem

Pluristem Therapeutics Inc. is a clinical development bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. Pluristem's first product, PLX-PAD (for the treatment of Peripheral Artery Disease), a “First-In-Human” placental-derived mesenchymal-like stromal cell product, has received both the FDA and Paul Erlich Institute (PEI) clearance and is being investigated in Phase I clinical trials. The Company is developing a pipeline of products derived from human placenta, a non-controversial, non-embryonic, adult stem cell source. The (PLacental eXpanded) cell products are stored off-the-shelf, ready-to-use, and require no histocompatibility matching.

The company's additional product candidates include PLX-IBD, targeting Inflammatory Bowel Disease, which includes Crohn's disease and Ulcerative Colitis; PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

See our product animation on YouTube: Animation, the content of which is not part of this press release.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at, the content of which is not part of this press release.



Contact: Pluristem Therapeutics Inc.
William Prather RPh, MD, +1-303-883-4954
Sr. VP Corporate Development
Russo Partners
Andreas Marathovouniotis, +1-212-845-4235



Posted: August 2009